Table 2.

Vismodegib pharmacokinetic parameters following oral administration of 150 mg vismodegib

Subject	t1/2 (days)	tmax* (h)	Cmax (µm)	AUC† (µm h)
Single dose
1	12.0	24.0	6.91	3130
2	13.3	48.0	6.76	4060
3	10.3	1.00	4.75	1980
4	8.83	1.00	5.98	2470
5	8.83	24.1	4.72	1590
6	14.3	24.0	6.57	3850
Mean	11.3	24.0	5.95	2850
%CV	20.4	1.00–48.0	16.7	35.1
Multiple dose
13	8.88	4.00	19.2	396
14	13.6	4.00	14.9	332
15	11.2	10.0	19.3	441
16	6.46	2.00	17.7	399
17	8.92	1.00	17.3	344
18	10.4	4.00	10.3	225
Mean	9.92	4.00	16.4	356
%CV	24.5	1.00–10.0	20.7	21.3

^*t_max summary statistics reported as median and range.

^†AUC is defined as the AUC (0,∞) for single dose group and AUC (0,24) on day 7 for multiple dose group. t_1/2, terminal phase half-life; t_max, time to maximum observed plasma concentration; C_max, maximum observed plasma concentration; AUC, area under the plasma concentration–time curve.